FDA's letter to health insurers about drug importation is meant to ensure they do not encourage policy holders to purchase drugs from outside the U.S., not to prohibit them from covering individuals who purchase Canadian drugs for personal use, FDA Commissioner McClellan told a Senate Appropriations/Agriculture Subcommittee hearing May 22
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.
In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.
Cell and gene therapy developers may not have to contend with HHS Secretary Robert F. Kennedy Jr.’s animosity like the traditional pharma industry, but his disinterest in distinguishing between the good and bad actors in the space could backfire.
